The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Clinical effect of temozolomide‐based chemotherapy in poorly differentiated endocrine carcinoma after progression on first‐line chemotherapy
Open accessAbstract
BACKGROUND: Patients with metastatic poorly differentiated endocrine carcinoma (PDEC) usually have a short survival. The chemotherapy combination of cisplatin and etoposide is frequently used as first‐line palliative chemotherapy. There are, however, no published studies concerning second‐line treatment of the disease. Temozolomide has shown clinical effect in well‐differentiated endocrine carcinomas. This study was performed to evaluate the effect of temozolomide in PDEC patients who had progressed on first‐line treatment. METHODS: Twenty‐five patients with PDEC (mainly gastrointestinal) were treated with temozolomide alone or in combination with capecitabine. A subset of patient also received bevacizumab. MGMT methylation was analyzed in tissue specimens. Data were collected retrospectively. RESULTS: One patient had a complete response, and 7 patients had partial response (33% response rate). Median duration of response was 19 months. Another 9 (38%) patients had a stable disease, after progression at inclusion, with a median duration of 18 months. Median progression‐free survival for all patients was 6 months, and median overall survival was 22 months. Only 1 patient had a MGMT methylation. CONCLUSIONS: Treatment with temozolomide alone or in combination with capecitabine and bevacizumab resulted in objective response or stabilization in 71% of PDEC patients who failed on first‐line chemotherapy. These results indicated that temozolomide may be used as second‐line treatment in PDEC. Cancer 2011;. © 2011 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma
Hegi, M. E., Diserens, A.-C., Gorlia, T., Hamou, M.-F., de Tribolet, N., Weller, M., Kros, J. M., Hainfellner, J. A., Mason, W., Mariani, L., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043331 · Cited by 7,405
Kwekkeboom, D. J., de Herder, W. W., Kam, B. L., van Eijck, C. H., van Essen, M., Kooij, P. P., Feelders, R. A., van Aken, M. O., & Krenning, E. P. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.2553 · Cited by 1,456
Moertel, C. G., Kvols, L. K., O'Connell, M. J., & Rubin, J. (1991) · Cancer · doi:10.1002/1097-0142(19910715)68:2<227::aid-cncr2820680202>3.0.co;2-i · Cited by 840
Strosberg, J. R., Fine, R. L., Choi, J., Nasir, A., Coppola, D., Chen, D., Helm, J., & Kvols, L. (2011) · Cancer · doi:10.1002/cncr.25425 · Cited by 766
Histological Typing of Endocrine Tumours
Solcia, E., Klöppel, G., & Sobin, L. H. (2000) · Springer eBooks · doi:10.1007/978-3-642-59655-1 · Cited by 747
Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin
Mitry, E., Baudin, E., Ducreux, M., Sabourin, J.-C., Rufié, P., Aparicio, T., Lasser, P., Elias, D., Duvillard, P., Schlumberger, M., et al. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690325 · Cited by 496
Temozolomide as Monotherapy Is Effective in Treatment of Advanced Malignant Neuroendocrine Tumors
Ekeblad, S., Sundin, A., Janson, E. T., Welin, S., Granberg, D., Kindmark, H., Dunder, K., Kozlovacki, G., Örlefors, H., Sigurd, M., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2053 · Cited by 473
Self-citationKulke, M. H., Hornick, J. L., Frauenhoffer, C., Hooshmand, S., Ryan, D. P., Enzinger, P. C., Meyerhardt, J. A., Clark, J. W., Stuart, K., Fuchs, C. S., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1476 · Cited by 381
Small-Cell Carcinomas of the Gastrointestinal Tract: A Review
Brenner, B., Tang, L. H., Klimstra, D. S., & Kelsen, D. P. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.09.075 · Cited by 294
Binderup, T., Knigge, U., Loft, A., Mortensen, J., Pfeifer, A., Federspiel, B., Hansen, C. P., Højgaard, L., & Kjaer, A. (2010) · Journal of Nuclear Medicine · doi:10.2967/jnumed.109.069765 · Cited by 279
Cited by
Pavel, M., Baudin, E., Couvelard, A., Krenning, E., Öberg, K., Steinmüller, T., Anlauf, M., Wiedenmann, B., & Salazar, R. (2012) · Neuroendocrinology · doi:10.1159/000335597 · Cited by 873
Self-citationENETS Consensus Guidelines Update for Neuroendocrine Neoplasms of the Jejunum and Ileum
Niederle, B., Pape, U.-F., Costa, F., Gross, D., Kelestimur, F., Knigge, U., Öberg, K., Pavel, M., Perren, A., Toumpanakis, C., et al. (2016) · Neuroendocrinology · doi:10.1159/000443170 · Cited by 474
Self-citationStrosberg, J. R., Halfdanarson, T. R., Bellizzi, A. M., Chan, J. A., Dillon, J. S., Heaney, A. P., Kunz, P. L., O’Dorisio, T. M., Salem, R., Segelov, E., et al. (2017) · Pancreas · doi:10.1097/mpa.0000000000000850 · Cited by 373
Gastroenteropancreatic high‐grade neuroendocrine carcinoma
Sorbye, H., Strosberg, J., Baudin, E., Klimstra, D. S., & Yao, J. C. (2014) · Cancer · doi:10.1002/cncr.28721 · Cited by 347
Self-citationA phase I/II study of rovalpituzumab tesirine in delta-like 3—expressing advanced solid tumors
Mansfield, A. S., Hong, D. S., Hann, C. L., Farago, A. F., Beltran, H., Waqar, S. N., Hendifar, A. E., Anthony, L. B., Taylor, M. H., Bryce, A. H., et al. (2021) · npj Precision Oncology · doi:10.1038/s41698-021-00214-y · Cited by 80
Metadata
- Authors
- Welin, S., Sorbye, H., Sebjornsen, S., Knappskog, S., Busch, C., & Öberg, K.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2011-03-31
- Volume
- 117
- Issue
- 20
- Pages
- 4617-4622
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W2079144528
- Cited by
- 288
- References
- 18
- FWCI
- 11.02
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Clinical effect of temozolomide‐based chemotherapy in poorly differentiated endocrine carcinoma after progression on first‐line chemotherapy. https://app.cochat.ai/papers/10.1002/cncr.26124
- The paper
- Welin, S., Sorbye, H., Sebjornsen, S., Knappskog, S., Busch, C., & Öberg, K. (2011). Clinical effect of temozolomide‐based chemotherapy in poorly differentiated endocrine carcinoma after progression on first‐line chemotherapy. Cancer. https://doi.org/10.1002/cncr.26124
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.